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1. Introduction  
Millions of people worldwide have orthodontic therapy for the treatment of dental 
malocclusions, craniofacial disorders, and simply to improve their appearance. However, 
orthodontic treatment has several major problems, including the long time braces must be 
worn, the pain involved during treatment, and the need to wear retainers to prevent relapse. 
Orthodontics could be improved. Understanding the mechanisms involved with 
orthodontic tooth movement represents a first step toward this goal. Improvements in the 
practice of orthodontics would have an immediate and significant impact on the millions of 
individuals undergoing orthodontic treatment worldwide.  
Orthodontic tooth movement can be thought of as an interaction of mechanical force on 
biological tissue (Krishnan and Davidovitch, 2006; Wise and King, 2008). Much progress in 
orthodontics has involved finding better means to apply mechanical force to teeth. While 
advances have been made regarding the mechanics and materials used in orthodontics, 
there has been a relative plateau in the overall treatment outcomes. For example, a 
moderately difficult case still requires an average of 18-36 months for treatment, no different 
than 50 years ago. It is apparent that discoveries relating to biological manipulations may 
provide a path for significantly improving orthodontic practice.  
It is thought that enhancing the speed of orthodontic tooth movement could be 
accomplished if bone remodeling occurred at an accelerated rate in the alveolar bone 
associated with the teeth being moved. While this has not been formally demonstrated in 
the clinic, animal studies strongly support this notion. For example, orthodontic tooth 
movement in a mouse model was accelerated by overexpressing Receptor Activator of 
Nuclear Factor Kappa B-Ligand (RANKL) (Kanzaki et al., 2006). RANKL promotes the 
formation and bone resorptive activity of osteoclasts, the specialized cells charged with bone 
resorption (Hofbauer and Heufelder, 2001). Conversely, inhibitors of osteoclast formation 
and activity including osteoprotegerin (OPG), integrin inhibitors, bisphosphonates and 
inhibitors of matrix metalloproteinases all slowed tooth movement (Holliday et al., 2003; 
Dolce et al., 2003; Kanzaki et al., 2004; Dunn et al., 2007). Although these studies showed 
that it is possible to manipulate the speed at which orthodontic tooth movement proceeds 
by altering osteoclast activity, the specific agents tested to date are probably inappropriate 
for orthodontic use in the clinic as there would be too much danger of off target effects. Such 
risks are unacceptable for orthodontic procedures. Although orthodontics as currently 
www.intechopen.com
 
Principles in Contemporary Orthodontics 
 
528 
practiced is imperfect, it is quite effective. Moreover, children are the most common patients 
in the orthodontic clinic; for biological manipulations to enhance orthodontics to be 
contemplated, they must be very safe. 
Biological manipulation might be useful in orthodontics to prevent relapse. It is possible that 
enhancers of bone formation rates might be used to remodel alveolar bone to reduce 
incidence of relapse and minimize the use of retainers. In this case, it is possible that 
uncoupled stimulators of bone formation (ie regulation that stimulates bone formation 
without corresponding bone resorption) might prove ideal. As will be described below, 
modulators of sclerostin signaling, or other regulators of the Wnt-signaling pathway, are 
obvious candidates for this application (Paszty et al., 2010; Moester et al., 2010). 
Pain is accepted as a necessary off target effect of orthodontics, and is typically treated 
using common non-prescription pain medications like acetaminophen. For theoretical 
reasons acetaminophen, which acts centrally, is considered better than ibuprophen or 
aspirin, which act on prostaglandins locally (Simmons and Brandt, 1992; Kehoe et al., 
1996; Walker and Buring, 2001). After an initial period of discomfort (a few days) pain 
goes away until the next activation of the appliance. The initial activation is usually 
considered the most painful. In general, orthodontic pain has been considered 
manageable and acceptable to patients, or at least to the patient’s parents, as a necessary 
component of orthodontic treatment. For this reason, despite its widespread use, 
relatively little effort has been expended to identify ways to reduce orthodontic pain. 
Interestingly, as more adults are undergoing orthodontic treatment, more attention has 
been paid to means for relieving orthodontic pain.  
It is thought that pain can be reduced by modifying orthodontic procedures, particularly by 
using lighter forces to cause less damage and inflammation. Treatment of orthodontic pain 
is complicated by the fact that tooth movement may require inflammation, triggered by 
mechanical damage to tissues of the periodontal ligament (PDL) and associated alveolar 
bone, which is caused by the application of orthodontic force. Efforts to reduce the 
inflammation either by reducing force or by using local anti-inflammatory agents may 
compromise the process of tooth movement (Simmons and Brandt, 1992; Kehoe et al., 1996; 
Walker and Buring, 2001). In fact, there are very few studies that objectively address any of 
these questions in humans or even in animal models (Bergius et al., 2000; Giannopoulou et 
al., 2006; Eversole, 2006). For example, there currently are no animal models for studying 
levels of orthodontic force compared with levels of pain and the amount of tooth movement. 
Without proper studies, opinions on pain in orthodontics are now based largely on 
anecdotal evidence.  
Orthodontic tooth movement is more complicated than simply applying force, causing 
mechanical damage and inflammation, followed by bone resorption as part of the response 
to inflammation and damage. Orthodontic tooth movement requires the presence of a 
functional PDL (Krishnan and Davidovitch, 2006; Wise and King, 2008). Ankylosed teeth do 
not move regardless of the amount of force applied to the tooth, or the amount of 
inflammation induced. The precise mechanisms by which the PDL transduces force to 
stimulate bone resorption to allow for movement of a tooth through bone are still 
mysterious. For example, it is known that RANKL is expressed at higher levels on the 
pressure side of a tooth, but the mechanism supporting the increased RANKL expression is 
not known.  
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Recent data demonstrate previously unsuspected links between the neural system and bone 
remodeling and offer potential strategies for improving orthodontic treatment. Taking 
advantage of these opportunities requires understanding in greater detail how the neural 
system is involved in the regulation of orthodontic tooth movement. Neurons and the bone 
cells involved in the remodelling required for orthodontic tooth movement share numerous 
molecular components and it may be possible to identify agents that can at the same time increase 
the speed of orthodontic tooth movement while reducing pain. Recent studies have indicated for 
example that the transient receptor potential (TRP) vanilloid 1 receptor (TRPV1), a key 
receptor in pain sensing, is also is expressed in osteoclasts (Rossi et al., 2009; Rossi et al., 
2011). TRPV1 is the receptor for capsaicin, the ingredient in red chili peppers that produces 
burning sensations (Caterina, 2007). Capsaicin and other TRPV1 agonists have been shown 
to stimulate osteoclast formation (Rossi et al., 2009). From this it is plausible that a single 
agent, an appropriate agonist of TRPV1, may be able to both relieve orthodontic pain and 
significantly reduce the time required for orthodontic procedures. Capsaicin is already a 
FDA-approved treatment for clinical pain and a number of studies have indicated that it is  
 
 
Fig. 1. Orthodontic tooth movement initiates with application of force (B) that compresses 
the PDL on the pressure side of the tooth, or stretches the periodontal ligament on the 
tension side. This leads to resorption on the pressure side and bone formation on the tension 
side (C) which accommodates the repositioning of the tooth (D). Goals of manipulation of 
tooth movement with bioactive agents include increasing the rate of tooth movement, 
reducing pain, and preventing relapse 
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effective in the reduction of pain measures for subjects suffering from arthritis, post-herpetic 
and diabetic neuropathies (Peikert et al., 1991; McCarthy and McCarty, 1992; Tandan et al., 
1992; Watson et al., 1993; Caterina, 2007). As such, an adapted approach might be feasible in 
the clinic using capsaicin, or other agonists of TRPV1, to easily and safely facilitate the goal 
of improving orthodontic outcomes. 
In summary, opportunities exist for improving orthodontic treatment by enhancing 
orthodontic tooth movement, preventing relapse, and reducing pain associated with 
orthodontic procedures (Figure 1). Recent advances in understanding neuromodulation of 
bone remodeling present new means to affect all of these parameters, perhaps by using the 
same therapeutic molecule. To examine this in greater detail we will first briefly consider the 
essential elements of the regulation of bone remodeling, then examine connections between 
bone cells and neurons. 
2. Bone remodeling 
Bone remodeling can be thought of simply as a dialog between two cell types, osteoclasts 
and osteoblasts  (Figure 2)(Martin et al., 2009). Osteoclasts are cells of the hematopoetic 
lineage that are specialized for bone resorption (Teitelbaum, 2007). Osteoblasts are 
mesenchymal and are specialized for bone formation (Askmyr et al., 2009). Although this is 
an oversimplification, for example T-cell are known to directly stimulate osteoclast 
formation and bone resorption (Weitzmann and Pacifici, 2005), and osteocytes are primary 





Fig. 2. RANKL produced by osteoblasts stimulates osteoclast formation and osteoclast bone 
resorption. Osteoprotengerin is also produced by osteoblasts and serves as a competitive 
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that a major element of the regulation of bone remodeling is through expression by 
osteoblasts of RANKL. This stimulates its receptor, RANK, present on the surface of 
osteoclast precursors and osteoclasts, which induces osteoclast differentiation, survival and 
bone resorptive activity (Burgess et al., 1999; Kong et al., 1999). Osteoprotegerin, also 
produced by osteoblasts, serves as a competitive inhibitor of RANKL and by doing so 
reduces bone resorption (Hofbauer et al., 2004). Neural regulation of bone remodeling must 
occur within the constraints of this regulatory system. 
 
  
Fig. 3. Sclerostin is thought to inhibit differentiation of osteoblasts from a stage where they 
promote osteoclastic bone resorption to a stage where they form bone. 
RANKL is a tumor necrosis factor (TNF)-related type II transmembrane protein expressed 
by osteoblasts, T-cells and a few other cell types (Xing et al., 2005). There was great 
excitement in the bone field in the late 1990s with the demonstration that RANKL was the 
long sought osteoclast differentiation factor (Lacey et al., 1998). Since the initial reports, this 
basic finding has been supported by a host of studies (Xing et al., 2005). RANKL binds its 
receptor RANK to stimulate osteoclast formation and activity. It also binds OPG, which 
resembles RANK but lacks a transmembrane domain, and serves as a soluble competitive 
inhibitor. Overwhelming evidence indicates the vital importance of this triad in bone 
remodeling and has led to the paradigm shown in Figure 2. With the discovery of RANKL 
came efforts to utilize inhibitors of RANKL in the development of pharmaceutical agents 
that inhibit osteoclast activity. Recently an anti-RANKL antibody-based pharmaceutical 
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(Denosumab) was generated by Amgen and approved as an anti-osteoporotic agent (Trade 
name Prolia) and for bone cancer (Xgeva) (Lewiecki, 2010; Castellano et al., 2011; Baron et 
al., 2011).  
Sclerostin has recently been identified as a vital regulator of bone formation (Moester et al., 
2010). Sclerostin is a controller of the Wnt-signaling pathway, which is crucial for 
modulating bone remodeling (Baron et al., 2006; Kubota et al., 2009). Sclerostin is thought to 
block the transition of osteoblasts from a step along their differentiation pathway where 
they produce RANKL, but do not form bone, to a point where they do not produce RANKL 
(or produce more osteoprotegerin) and do form bone (Figure 3)(Paszty et al., 2010). Thus 
higher levels of sclerostin will favor bone resorption and lower levels will favor bone 
formation. Taking advantage of this paradigm, efforts are underway to transition a 
humanized monoclonal antibody inhibitor of sclerostin to the clinic for the treatment of 
osteoporosis (Lewiecki, 2011). Sclerostin is one of several molecules that influence osteoblast 
activity by regulating the Wnt-signaling pathway (Baron et al., 2006).  
3. Central control of bone remodeling 
During the past decade evidence has accumulated that has shown that levels of bone 
remodeling and final bone structure is regulated in the central nervous system (Elefteriou, 
2008; Wong et al., 2008; Karsenty and Oury, 2010). Three different mechanisms will be 
discussed in some detail, regulation through leptin signaling, neuropeptide Y and 
cannibanoid receptors. It is postulated that central regulation of bone remodeling represents 
a link with bone remodeling and energy metabolism (Karsenty and Oury, 2010). Leptin 
release by the hypothalamus for example has been shown to regulate both bone remodeling 
and insulin secretion (Baldock et al., 2002; Takeda, 2008; Kalra et al., 2009; Confavreux et al., 
2009; Baldock et al., 2009; Qin et al., 2010; Zengin et al., 2010). Leptin is a 16 kD adipose-
derived protein hormone, which plays a key role in regulating energy intake and 
expenditure. It has a major role in controlling appetite and metabolism. 
Evidence suggests that leptin-regulated neural pathways control both bone formation and 
bone resorption. Mice lacking the gene encoding leptin (ob/ob) are obese and have higher 
bone mass than normal and higher rates of bone remodeling (Elefteriou et al., 2005). 
Intracerebroventricular infusion of leptin into the mice, under conditions where little or no 
leptin leaked into general circulation, led to normalization of both rates of bone remodeling 
and bone mass (Elefteriou et al., 2005). This strongly supported the idea that leptin regulates 
bone remodeling through a central relay, and this mode of regulation is vitally important in 
maintaining bone  (Kalra et al., 2009; Karsenty and Oury, 2010).  
The leptin receptor is expressed on three types of hypothalamic neurons, although its 
expression in the brain is not restricted to hypothalamic neurons (Karsenty and Ducy, 2006; 
Kalra et al., 2009). The three neurons in the hypothalamus are the arcuate nucleus, the 
ventromedical hypothalamic nucleus, and paraventricular nuclei. Lesioning of the arcuate 
nucleus using two independent strategies did not affect bone mass directly, or alter the 
ability of infusion of leptin to affect bone mass (Takeda and Karsenty, 2008). In contrast, 
lesioning ventromedical hypothalamic nuclei neurons in wild type animals resulted in a 
high bone mass/high bone turnover phenotype similar to that observe in the ob/ob mice. 
Infusion of leptin failed to normalize the bone phenotype in either lesioned wild type mice 
or the ob/ob mice (Guidobono et al., 2006). Taken together, these data suggested that the 
ventromedical hypothalamic nucleus neurons are required for leptin-dependent central 
regulation of bone remodeling. 
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Fig. 4. Leptin stimulates receptors in the brain stem and hypothalamus leading to 




Fig. 5. Leptin stimulates  cocaine- and amphetamine- regulated transcript expression which 
acting through the sympathetic nervous system to stimulate  both increased bone formation 
by osteoblasts and increased resorption by osteoclasts 
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How then is this regulation mediated? One route is through dopamine β-hydroxylase, an 
enzyme required for the production of norepinepherine and epinephrine (Figure 4) (Yadav 
and Karsenty, 2009; Yadav et al., 2009). Mice lacking dopamine β-hydroxylase have a similar 
bone phenotype to the ob/ob mice, and leptin infusion of these mice failed to normalize bone 
parameters. Only one adrenergic receptor is expressed in osteoblasts, β2 adrenergic receptor. 
Mice lacking one or both copies of the β2 adrenergic receptor developed a high bone mass 
phenotype, and leptin infusion into mice lacking the β2 adrenergic receptor decreased fat 
mass but did not normalize the bone parameters (Yadav and Karsenty, 2009; Yadav et al., 
2009).  
Another mechanism by which leptin mediates bone remodeling is via the cocaine- and 
amphetamine- regulated transcript (CART), a neuropeptide precursor protein (Figure 5) 
(Elefteriou et al., 2005). The level of CART expression in the hypothalamus and peripheral 
organs including the pancreas and adrenal glands is tied to levels of leptin. Simply, CART 
expression is stimulated by leptin, and osteoclastic resorption decreases in relation to the 
amount of CART expressed. This action of CART is mediated through osteoblasts; CART 
represses RANKL expression of osteoblasts and thus reduces osteoclast formation and bone 
resorption (Elefteriou et al., 2005). 
Neuromedin U is a neuropeptide expressed in hypothalamic neurons and in the small 
intestine has also been also been implicated as a component of the leptin regulatory 
pathway (Figure 6) (Sato et al., 2007). Although its receptor is not detected in bone cells, 
knockout of neuromendin U leads to a high bone mass phenotype. Treatment of leptin 
deficient mice with neurmedin U resulted in partial rescue of the high bone mass 




Fig. 6. Leptin also signals through the hypothalamus using a pathway involving 
neuromedin U and the sympathetic nervous system leading to stimulation of β2 adrenergic 
receptor which decreases bone formation 
Taken together this suggested that leptin regulates bone remodeling through several 
pathways. Although caution must be exercised in translating these results to humans, they 
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suggest a number of ramifications for humans with respect to orthodontic procedures. First, 
alterations in elements of this signaling pathway, for example single nucleotide 
polymorphisms (SNPs) in one or more the genes encoding elements of the pathway may 
have consequences for the general rate and efficacy of orthodontic procedures in an 
individual. For example, an SNP in β2 adrenergic receptor that increases signaling from the 
receptor may be associated with higher than normal bone mineral density, and increased 
rates of tooth movement.  
 
 
Fig. 7. Neuropeptide Y signals through Y2R receptors in the hypothalamus and Y1R 
receptors in osteoblasts to decrease osteoblast activity 
Secondly, direct local stimulation of osteoblasts in the alveolar bone associated with specific 
teeth with β2 adrenergic receptor agonists might both enhance rates of tooth movement and 
increase the speed of bone formation at the tension side of the tooth, perhaps reducing the 
tendency to relapse. However, care would have to be taken in manipulating these pathways 
because of the associations of the adrenergic systems with cardiovascular diseases (Saini-
Chohan and Hatch, 2009). In addition, a recent study indicated that SNPs in the β2 
adrenergic receptor are associated with heterotypic ossification, which is associated with 
higher rates of fractures. Moreover, recent studies of bisphosphonate-associated oral 
osteonecrosis suggests that the condition is actually osteosclerosis, and may result from 
disorganization of normal bone remodeling rather than blocking of the process (Chiu et al., 
2010; Treister et al., 2010). While perturbation in normal bone remodeling on the surface may have 
favorable outcomes, great care must be taken due to the complexity of bone formation and remodeling 
which can lead to unexpected adverse consequences.  
Neuropeptide Y, a neurotransmitter that is widely expressed in both central and peripheral 
nervous systems, has been shown to regulate bone remodeling (Baldock et al., 2007; Baldock 
et al., 2009)(Figure 7). Knockout mice of either the neuropeptide Y1 or Y2 receptors yielded a 
high bone mass phenotype with enhanced osteoblast activity (Baldock et al., 2009). 
Neuropeptide Y receptors are, like the leptin receptor, expressed by cells of the 
hypothalamus. Knockout of Y2 in the hypothalamus is sufficient to induce a high bone 
density phenotype. However, knockout of Y1 in the hypothalamus did not alter bone 
homeostasis (Baldock et al., 2002; Baldock et al., 2007).  
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Fig. 8. Cannabinoid stimulate a central response that leads to decreased bone formation. The 
CB2 receptor of osteoclasts reduces osteoclast activity, but CB1 stimulation increases 
expression of RANKL which is pro-stimulatory 
Recently, the Y1 receptor was knocked out specifically in osteoblasts using a Cre/Lox 
system (Baldock et al., 2007). It was shown that osteoblast specific knockout of Y1 was 
sufficient to increase bone mass and enhance bone remodeling. These data indicated that 
neuropeptide Y signaling could have a role in both central and local neural control of bone 
remodeling.  
Neuropeptide Y signaling has been linked to food intake and like leptin, there are links 
between neuropeptide Y signaling and obesity (Munoz and Argente, 2002; Feletou and 
Levens, 2005). Neuropeptide Y receptors are found on pre- and post-synaptic neurons. 
Presumably activation of the receptors is tied to behavioral changes leading to alterations in 
food consumption. Whether it is possible to take advantage of neuropeptide Y signaling to 
influence bone remodeling associated with orthodontic applications is not clear, but most 
likely, means would have to be devised to deliver agonists locally. 
A third route by which bone remodeling can be regulated centrally in through 
endocannabinoid signaling, which has been shown modulate bone remodeling through 
central and peripheral cannabinoid receptors(Davenport, 2005; Rossi et al., 2009) (Figure 8). 
Cannabinoid receptors are a class of G protein coupled membrane receptors. The 
cannabinoid receptors CB1 and CB2 play a key role in the maintenance of bone mass and are 
expressed on osteoblasts, osteoclasts and osteocytes.  Deficiency in the hypothalamic 
receptor CB1 in mice has been shown to accelerate age-dependent osteoporosis. Agonists of 
CB2 reduce bone loss after ovariectomy in rodent models while increasing the thickness of 








Fig. 9. V-ATPases are ubiquitously-expressed and are composed of many subunits. Some 
subunits are present in multiple isoforms. Osteoclasts, for example, contain the 
“housekeeping” isoforms of subunit a (a1, and a2) and the also express the a3 subunit which 
is required for bone resorption. ATP6AP2 (the prorenein receptor) links bone resorption to  
rennin/angiotensin signalling. 
4. Common molecular features shared by neurons and bone cells 
4.1 Specialized machinery for acidification 
Evidence has emerged that osteoclasts share a number of molecular features with neural 
cells. These include the specialized use of vacuolar H+-ATPase (V-ATPase), chloride channel 
protein 7 (CLC-7), which work in coordination in order to properly acidify compartments 
(Schaller et al., 2005; Hinton et al., 2009). 
The V-ATPase is a multisubunit enzyme (11-13 subunits) that is expressed in all cells and is 
required for “housekeeping” acidification of vesicular compartments including lysosomes, 
late endosomes, compartments of uncoupling receptor and ligand, elements of the golgi, 
and phagosomes (Hinton et al., 2009). Certain specialized cell types express both the 
housekeeping subset of V-ATPases, and in addition, an additional subset that is involved in 
the specialized function of the cell type (Figure 9).  
Osteoclasts, which are specialized to resorb bone, are a clear and well-characterized example 
of a cell type that uses V-ATPases for a specialized function (Blair et al., 1989; Holliday et al., 
2005). Osteoclasts express normal housekeeping V-ATPases (Toyomura et al., 2003). In 
addition, they express a large subset that is destined for the plasma membrane of resorbing 
cells. When an osteoclast contacts activation signals associated with the bone surface, the 
specialized subset of V-ATPases is transported to a subdomain of the plasma membrane 
called the ruffled plasma membrane or ruffled border (Blair et al., 1989). These V-ATPases 
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then use ATP hydrolysis to pump protons against an electrochemical gradient to acidify an 
extracellular resorption compartment (Figure 10).  
Different subsets of V-ATPases are distinguished by isoforms of particular subunits. Some 
subunits are present in only a single form and are present in all V-ATPases no matter what 
their function. Others have multiple isoforms that are derived from different genes. For 
example, there are four isoforms of the a subunit (a1-a4). Subunits a1 and a2 are found in the 
housekeeping V-ATPases. The a3-subunit has been identified at high levels in osteoclasts, 
pancreatic beta cells, kidney epithelial cells and microglia (Li et al., 1999; Smith et al., 2001; 
Sun-Wada et al., 2006; Serrano et al., 2009). The a4 subunit is restricted to epithelial cells of 
the kidney (Stover et al., 2002).  
 
 
Fig. 10. Osteoclasts insert V-ATPases into the plasma membrane is a region known as the 
ruffled border. V-ATPases pump protons into the resorption compartment lowering the pH, 
which is crucial for bone resorption. TRPV1 is expressed on both osteoclasts, where agonists 
are proresorptive, and on neurons, where agonists reduce pain. This makes it possible that a 
single therapeutic agent can both increase the rate of tooth movement (which requires 
increased osteoclastic resorption) and reduce pain associated with orthodontic procedures. 
Like osteoclasts, neurons also express subsets of V-ATPases that are utilized for specialized 
purposes (Moriyama et al., 1992). Neurons are thought to utilize V-ATPases to generate a 
driving force to power loading synaptic vesicles with neurotransmitters. In addition, there is 
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considerable evidence that a subunit is intimately involved in mediating the fusion of 
synaptic vesicles with the plasma membrane to allow dumping of neurotransmitters into the 
synaptic cleft (Hiesinger et al., 2005; Di et al., 2010). 
Among the most exciting recent findings was the demonstration that a V-ATPase accessory 
protein, the pro-renin receptor (PRR, also known as ATP6AP2) forms a vital scaffold 
between V-ATPase and the Wnt-signaling pathway (Cruciat et al., 2010). Without PRR, 
mineralization was blocked in a mouse model. Whether PRR is also found in osteoclasts is 
not known, and whether the recent demonstration that PRR is found in the hypothalamus 
suggests that it may be another molecule by which central regulation of bone remodeling 
might occur remains to be explored (Takahashi et al., 2010). In this case, the primary known 
function of PRR is its involvement in renin-angiotensin signaling which is related to blood 
pressure and cardiac activity (Nguyen, 2011).  
Along with sharing specialized functions of V-ATPases, both neurons and osteoclasts 
require the voltage–gated chloride channel CLC-7. This channel is thought to open to reduce 
voltage across membranes produced by the activity of electrogenic V-ATPases. Mutations in 
CLC-7 lead to both osteopetrosis and neurodegeneration (Kornak et al., 2001; Kasper et al., 
2005) 
4.2 Sensing receptors shared by neurons and osteoclasts 
Both bone remodeling and sensory pain pathways share common inflammatory mediators, 
including TNF-, prostaglandins, interleukins, and vasoactive neuropeptides (e.g., 
substance P), to name a few. Again, specifically targeting the intersection of these pathways 
may provide unique opportunities for development of innovative therapies related to bone 
disorders and specifically OTM. The transient receptor potential (TRP) channels is a class of 
receptors that are involved in sensory and pain processing. For example, The TRP vanilloid 
1 receptor (TRPV1) is found primarily on neuronal c- and a- fiber nociceptors that are 
responsible for thermal/burning pain. TRPV1 is also a major transducer of inflammatory 
pain, especially under acidic conditions. Recent work demonstrated that TRPV1 is expressed 
in human osteoclasts, indicating that TRPV1 may promote bone resorption (Rossi et al., 
2009; Rossi et al., 2011). Previous work with ultrapotent TRPV1 agonists such as 
resiniferatoxin (RTX) indicates that inflammatory pain can be eliminated (Neubert, et al. 
2008). TRPV1 is activated in response to lowered pH, which is an important regulator of 
local bone resorption. TRPV1 is expressed on osteoclasts and agonists of TRPV1, capsaicin 
and resinoferotoxin (RTX), stimulate osteoclast differentiation at concentrations where 
neuronal pain sensors are not inactivated (Rossi et al., 2009; Rossi et al., 2011). Interestingly, 
agonists of TRPV1 induce overexpression of the cannabinoid receptor CB2 (Rossi et al., 2009; 
Rossi et al., 2011). The TRPV1 inhibitor capsazepine was also shown to inhibit both 
osteoclast and osteoblast differentiation (Idris et al., 2010). Together, this makes TRPV1 a 
potential integrator between the central nervous system and bone which may be involved in 
orchestrating both local bone remodeling changes in response to pH and possibly 
orthodontic force, and augmenting central modulation of bone remodeling. These data 
suggest that well documented agonists and antagonists of TRPV1 may prove to be ideal 
agents for manipulation of OTM in ways by which orthodontic practice may be  
improved. Increased understanding of OTM can also provide insight into mechanisms of 
bone biology.  
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Interestingly, agonists of TRPV1 induce overexpression of the cannabinoid receptor CB2 
(Rossi et al., 2009; Rossi et al., 2011). Increased understanding of OTM can provide insight 
into mechanisms of bone biology. For example, this knowledge may have direct 
implications for the use of TRPV1 agonists in the treatment of pain and bone destruction 
associated with bone cancer [10] (Figure 10). 
5. Summary 
Biological manipulation to improve orthodontic procedures is in its infancy, but it appears 
possible to both improve the speed and efficacy of tooth movement, and to reduce 
associated discomfort. Proof-in-principle experiments have been performed in animal 
models but translation to the clinic will require greater understanding of the processes 
involved. Recent studies uncovering mechanisms by which bone remodeling is controlled 
by central mechanisms and demonstrating that osteoclasts and neurons share regulatory 
molecules, although they are used for different purposes, open new avenues for 
understanding and manipulating orthodontic tooth movement and perhaps simultaneously 
reducing the discomfort associated with the procedures.  
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